<DOC>
	<DOCNO>NCT01369875</DOCNO>
	<brief_summary>Background : - Tumor infiltrate lymphocyte ( TIL ) white blood cell take tumor tissue . The cell modify help kill tumor cell , give back person cancer . By give cell patient , researcher hope improve current treatment available patient melanoma respond standard therapy . The TIL give treatment suppress immune system . This make easy TIL attack cancer cell . The TIL also give aldesleukin ( IL-2 ) , design help keep TIL cell alive body . Objectives : - To study safety effectiveness specially modified tumor infiltrate lymphocyte treat melanoma respond treatment . Eligibility : - Individuals least 18 year age metastatic melanoma respond treatment . Design : - Participants screen physical exam medical history . They also blood test image study . - A piece tumor collect white blood cell separate make TIL treatment . - Participants take drug suppress immune system 7 day start treatment . - Participants receive TIL single dose . Then receive IL-2 every 8 hour 15 dos . Participants remain hospital 2 week treatment . They monitor frequent blood test study . - After leave hospital , participant regular followup visit every 1 4 month first year . Then return followup every 3 4 month , direct study researcher .</brief_summary>
	<brief_title>Modified Tumor Infiltrating Lymphocytes Metastatic Melanoma</brief_title>
	<detailed_description>Background : - Tumor Infiltrating Lymphocyte ( TIL ) administration high dose interleukin ( IL ) -2 follow lymphodepletion mediate durable complete response patient refractory melanoma . Obstacles administration therapy include failure establish TIL vitro 20 % patient , long delay tumor resection TIL establishment result poor TIL attribute therapy patient ineligibility due progression , requirement large number feeder cell TIL expansion therapeutic number . - The K562 cell line engineer express 4-1BBL costimulatory molecule CD64 ( high affinity Fc receptor load antibody OKT3 ) . The K562.CD64.4-1BBL Engineered Cells Costimulation Enhancement ( ECCE ) replace 75 % feeder cell large scale TIL expansion . ECCE add tumor cell suspension provide costimulation trans result rapid reliable lymphocyte growth even tumor TIL growth standard condition . - A cloned K562.CD64.4-1BBL-7F11 ECCE line produce Good Manufacturing Practice ( GMP ) condition master cell bank generate . An optimized protocol establish rapidly expand ( REP ) young TIL use minimum feeder 7F11 . These ECCE REPed TIL retain tumor recognition attribute standard TIL , differ standard TIL contain few CD4+ cell natural killer cell . When 7F11ECCE add directly single cell tumor suspension , young TIL culture reliably generate even patient otherwise would standard young TIL culture treatment . Objectives : Primary objective : - In cohort 1 , evaluate whether young TIL rapidly expand use 7F11 ECCE replace feeder cell administer IL-2 patient follow non -myeloablative conditioning regimen result clinical tumor regression patient refractory metastatic melanoma . - In Cohort 2 , evaluate whether young TIL generate use trans costimulation 7F11 ECCE patient standard young TIL grow mediate tumor regression nonmyeloablative conditioning high dose IL-2 patient refractory metastatic melanoma . - Determine toxicity ECCE young TIL treatment regimens Eligibility : Patients 18 year age old must : - metastatic melanoma ; - Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 - One lesions 2 cm great suitable resection TIL culture Patients may : - Concurrent major medical illness ; - Any form immunodeficiency ; - Severe hypersensitivity agent use study ; - Contraindications high dose IL-2 administration . Design : - Patients undergo resection obtain tumor generation autologous young TIL culture . - Parallel TIL culture establish use ) standard technique IL-2 b ) Engineered Cells Costimulation Enhancement ( ECCE ) protocol use irradiate K562.CD64.4-1BBL-7F11 ( 7F11 ) cell . - After 10 20 day culture undergo evaluation TIL establishment . Standard TIL use preferentially patient TIL establish standard method assign Cohort 1 - Cohort 1 : - TIL undergo ECCE REP exposure OKT-3 , IL-2 , feeder cell irradiate 7F11 . - Patients receive non-myeloablative lymphocyte deplete preparative regimen cyclophosphamide ( 60 mg/kg/day intravenous ( IV ) ) day -7 -6 fludarabine ( 25 mg/m^2/day IV ) day -5 -1 . - On day 0 patient receive infusion autologous young TIL begin highdose aldesleukin ( 720,000 IU/kg IV every 8 hour 15 dos ) . - Clinical immunologic response evaluate 4-6 week treatment . - Using optimal two-stage Phase II design , initially 18 patient enrol , three first 18 patient clinical response ( partial response ( PR ) complete response ( CR ) ) , accrual continue 35 patient , target 30 % goal objective response . - If standard young TIL fail grow ECCE young TIL evaluate patient ECCE TIL available assign Cohort 2 . - Cohort 2 : - Cultures patient Cohort 2 evaluate ECCE TIL establishment . If adequate ECCE TIL available , TIL undergo ECCE REP exposure OKT-3 , IL-2 , feeder cell irradiate 7F11 . - Patients receive non-myeloablative lymphocyte deplete preparative regimen cyclophosphamide ( 60 mg/kg/day IV ) day -7 -6 fludarabine ( 25 mg/m^2/day IV ) day -5 -1 . - On day 0 patient receive infusion autologous young TIL begin highdose aldesleukin ( 720,000 IU/kg IV every 8 hour 15 dos ) . - Clinical immunologic response evaluate 4-6 week TIL infusion . - Using small optimal two-stage Phase II design , initially 9 patient enrol , one first 9 patient clinical response ( PR CR ) , accrual continue 24 patient , target 25 % goal objective response . - If TIL culture establish either standard method ECCE young TIL protocol , patient eligible re-resection evaluation TIL different site .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Skin Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<criteria>INCLUSION CRITERIA : 1 . Measurable metastatic melanoma least one lesion resectable tumor infiltrate lymphocyte ( TIL ) generation . 2 . Patients 3 less brain metastasis eligible . Note : If lesion symptomatic great equal 1 cm , lesion must treat stable 3 month patient eligible . 3 . Greater equal 18 year age . 4 . Willing sign durable power attorney 5 . Able understand sign Informed Consent Document 6 . Clinical performance status Eastern Cooperative Oncology Group ( ECOG ) 0 1 . 7 . Life expectancy great three month . 8 . Patients gender must willing practice birth control time enrollment study four month receive preparative regimen . 9 . Serology : 1 . Seronegative human immunodeficiency virus ( HIV ) antibody . ( The experimental treatment evaluate protocol depends intact immune system . Patients engineer cell costimulation enhancement ( ECCE ) TIL 14 HIV seropositive decrease immunecompetence thus less responsive experimental treatment susceptible toxicity . ) 2 . Seronegative hepatitis B antigen , seronegative hepatitis C antibody . If hepatitis C antibody test positive , patient must test presence antigen reverse transcription polymerase chain reaction ( RTPCR ) hepatitis C virus ribonucleic acid ( HCV RNA ) negative . 3 . Women childbearing potential must negative pregnancy test potentially dangerous effect preparative chemotherapy fetus . 10 . Hematology : 1 . Absolute neutrophil count great 1000/mm^3 without support filgrastim . 2 . White blood cell ( WBC ) ( &gt; 3000/mm^3 ) . 3 . Platelet count great 100,000/mm^3 . 4 . Hemoglobin great 8.0 g/dl . 11 . Chemistry : 1 . Serum alanine aminotransferase ( ALT ) /aspartate aminotransferase ( AST ) less equal 2.5 time upper limit normal . 2 . Serum creatinine less equal 1.6 mg/dl . 3 . Total bilirubin less equal 1.5 mg/dl , except patient Gilbert 's Syndrome must total bilirubin less 3.0 mg/dl . 12 . More four week must elapse since prior systemic therapy time patient receives preparative regimen , patient ' toxicity must recover grade 1 less ( except toxicity alopecia vitiligo ) . Patients may undergo minor surgical procedure within past 3 week , long toxicity recover grade 1 less . 13 . Six week must elapse since prior anticytotoxic Tlymphocyte antigen 4 ( CTLA4 ) antibody therapy allow antibody level decline . 14 . Patients previously receive antiCTLA4 antibody document gastrointestinal ( GI ) toxicity must normal colonoscopy normal colonic biopsy . EXCLUSION CRITERIA : 1 . Women childbearing potential pregnant breastfeed potentially dangerous effect preparative chemotherapy fetus infant . 2 . Systemic steroid therapy require . 3 . Active systemic infection , coagulation disorder major medical illness cardiovascular , respiratory immune system , myocardial infarction , cardiac arrhythmia , obstructive restrictive pulmonary disease . 4 . Any form primary immunodeficiency ( Severe Combined Immunodeficiency Disease ) . 5 . Concurrent opportunistic infection ( The experimental treatment evaluate protocol depends intact immune system . Patients ECCE TIL 15 decrease immune competence may less responsive experimental treatment susceptible toxicity ) . 6 . History severe immediate hypersensitivity reaction agent use study . 7 . History coronary revascularization ischemic symptom 8 . Any patient know leave ventricular ejection fraction ( LVEF ) less equal 45 % . 9 . Documented LVEF less equal 45 % tested patient : Clinically significant atrial and/or ventricular arrhythmia include limited : atrial fibrillation , ventricular tachycardia , second third degree heart block Age great equal 60 year old 10 . Documented forced expiratory volume 1 ( FEV1 ) less equal 60 % predict tested patient : A prolonged history cigarette smoking Symptoms respiratory dysfunction</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Immunotherapy</keyword>
	<keyword>Cell Therapy</keyword>
	<keyword>Metastatic Cancer</keyword>
	<keyword>Melanoma</keyword>
	<keyword>Metastatic Melanoma</keyword>
	<keyword>Skin Cancer</keyword>
</DOC>